INO Cash-Secured Put Strategy

INO (Inovio Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital.

INO (Inovio Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $71.8M, a beta of 1.44 versus the broader market, a 52-week range of 1.03-2.98, average daily share volume of 2.3M, a public-listing history dating back to 1998, approximately 134 full-time employees. These structural characteristics shape how INO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.44 indicates INO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a cash-secured put on INO?

A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.

Current INO snapshot

As of May 15, 2026, spot at $1.31, ATM IV 190.95%, IV rank 40.04%, expected move 54.74%. The cash-secured put on INO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.

Why this cash-secured put structure on INO specifically: INO IV at 190.95% is mid-range versus its 1-year history, so the credit collected on a INO cash-secured put sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 54.74% (roughly $0.72 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated INO expiries trade a higher absolute premium for lower per-day decay. Position sizing on INO should anchor to the underlying notional of $1.31 per share and to the trader's directional view on INO stock.

INO cash-secured put setup

The INO cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With INO near $1.31, the first option leg uses a $1.24 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed INO chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 INO shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Sell 1Put$1.24N/A

INO cash-secured put risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.

INO cash-secured put payoff curve

Modeled P&L at expiration across a range of underlying prices for the cash-secured put on INO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use cash-secured put on INO

Cash-secured puts on INO earn premium while a trader waits to acquire INO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning INO.

INO thesis for this cash-secured put

The market-implied 1-standard-deviation range for INO extends from approximately $0.59 on the downside to $2.03 on the upside. A INO cash-secured put lets a trader earn premium while waiting to acquire INO at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current INO IV rank near 40.04% is mid-range against its 1-year distribution, so the IV signal is neutral; the cash-secured put thesis on INO should anchor more to the directional view and the expected-move geometry. As a Healthcare name, INO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to INO-specific events.

INO cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. INO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move INO alongside the broader basket even when INO-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on INO carry tail risk when realized volatility exceeds the implied move; review historical INO earnings reactions and macro stress periods before sizing. Always rebuild the position from current INO chain quotes before placing a trade.

Frequently asked questions

What is a cash-secured put on INO?
A cash-secured put on INO is the cash-secured put strategy applied to INO (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With INO stock trading near $1.31, the strikes shown on this page are snapped to the nearest listed INO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are INO cash-secured put max profit and max loss calculated?
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the INO cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 190.95%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a INO cash-secured put?
The breakeven for the INO cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current INO market-implied 1-standard-deviation expected move is approximately 54.74%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a cash-secured put on INO?
Cash-secured puts on INO earn premium while a trader waits to acquire INO stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning INO.
How does current INO implied volatility affect this cash-secured put?
INO ATM IV is at 190.95% with IV rank near 40.04%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related INO analysis